Toll Free: 1-888-928-9744

Cryptosporidiosis - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 28 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cryptosporidiosis - Pipeline Review, H1 2016


Global Markets Direct's, 'Cryptosporidiosis - Pipeline Review, H1 2016', provides an overview of the Cryptosporidiosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Cryptosporidiosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Cryptosporidiosis
- The report reviews pipeline therapeutics for Cryptosporidiosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Cryptosporidiosis therapeutics and enlists all their major and minor projects
- The report assesses Cryptosporidiosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Cryptosporidiosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cryptosporidiosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cryptosporidiosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Cryptosporidiosis Overview 5 Therapeutics Development 6 Pipeline Products for Cryptosporidiosis - Overview 6 Pipeline Products for Cryptosporidiosis - Comparative Analysis 7 Cryptosporidiosis - Therapeutics under Development by Companies 8 Cryptosporidiosis - Therapeutics under Investigation by Universities/Institutes 9 Cryptosporidiosis - Pipeline Products Glance 10 Early Stage Products 10 Cryptosporidiosis - Products under Development by Companies 11 Cryptosporidiosis - Products under Investigation by Universities/Institutes 12 Cryptosporidiosis - Companies Involved in Therapeutics Development 13 Dafra Pharma International Ltd. 13 ioGenetics, Inc. 14 Romark Laboratories, L.C. 15 Cryptosporidiosis - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Cryptosporidiosis - Dormant Projects 25 Cryptosporidiosis - Discontinued Products 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 27 Disclaimer 28
List of Tables
Number of Products under Development for Cryptosporidiosis, H1 2016 6 Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Number of Products under Investigation by Universities/Institutes, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Products under Investigation by Universities/Institutes, H1 2016 12 Cryptosporidiosis - Pipeline by Dafra Pharma International Ltd., H1 2016 13 Cryptosporidiosis - Pipeline by ioGenetics, Inc., H1 2016 14 Cryptosporidiosis - Pipeline by Romark Laboratories, L.C., H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Cryptosporidiosis - Dormant Projects, H1 2016 25 Cryptosporidiosis - Discontinued Products, H1 2016 26

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.